Nuvalent Inc (NUVL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $123.96 (+0.02%), Market cap $8.08B, 52-week low–high $71.43 ~ $111.99.
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent
Financial statements, price targets, institutional (13F) holdings and related news for Nuvalent Inc are updated in real time on BlackAll Trade.
Nuvalent Inc trades at $123.96 (+0.02%). Real-time quotes and charts are available on BlackAll Trade.
Nuvalent Inc has a market cap of about $8.08B.
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selec